Mindestbestellung 120 EUR Kostenlose Lieferung ab 250 EUR Bereit zur Abholung dead drop: in 5 Min. abholen Kostenloser Versand ab 250 EUR Aktionen

Substanzen · Tryptamin-Derivate

5-MeO-MiPT

C15H22N2O CAS 96096-55-8 Nur für analytische Forschungszwecke — nicht für den menschlichen Verzehr
Bevorzugter Name
5-MeO-MiPT
IUPAC-Name
N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine
CAS-Nummer der Stammverbindung (Referenz)
96096-55-8
Summenformel
C15H22N2O
Molekulargewicht
246.35 g/mol
InChIKey
HEDOODBJFVUQMS-UHFFFAOYSA-N
PubChem
CID 2763156
Quelle
PubChem
Geprüfte Synonyme und Katalogkürzel
5-Methoxy-N-methyl-N-isopropyltryptamine 5MeOMiPT 5-MeO MiPT

Passende Artikel im aktuellen Shop-Katalog

Geprüftes Pharmakologie- & Toxikologie-Dossier

5-MeO-MiPT (Moxy)

Psychedelic / entactogen (5-HT1A and 5-HT2A agonist) Substituted tryptamine (5-methoxy-N-methyl-N-isopropyltryptamine)
Geprüfte PubChem- & CAS-Identität C15H22N2O · CAS 96096-55-8 · CID 2763156
Kalibrierte Lieferform Reines Kristall / Analyse-Pulver (≥98 %)
≥98 % analytische Reinheit geprüft 246.35 g/mol
WHO-, PubMed- & PubChem-Quellen 3 cited records

Rezeptor-Telemetrie & Wirkmechanismus

5-HT₂ₐ Perceptual & Visual Signaling Partial Agonist
5-HT₁ₐ / 5-HT₂c Serotonergic Modulation Active
D₂ / Adrenergic Dopaminergic / Somatic Tone Low-Moderate

5-MeO-MiPT combines a 5-methoxy indole with an N-methyl-N-isopropyl side chain. It is a 5-HT1A/5-HT2A agonist with a stimulating, tactile, and erotic bias and relatively modest open-eye visuals compared with 4-HO-MET or 4-HO-MiPT. Body load, nausea, and vasoconstriction are prominent.

Biotransformation & Active Metabolites

The parent compound is active orally, unlike 5-MeO-DMT. MAO still matters: an MAOI is not required for activity and makes the interaction dangerous. It is not 5-MeO-DMT (CAS 1019-45-0) and not 4-HO-MiPT (CAS 77872-43-6).

Zeitliche Pharmakokinetik

Stimulating, body-heavy, tactile psychedelic with entactogenic warmth, nausea, and fewer geometric visuals than the 4-hydroxy tryptamines.

  1. Onset 20–40 minutes
  2. Peak Window 2–3 hours
  3. Total Window 5–8 hours
  4. Residual / Half-Life After-effects 2–4 hours of residual stimulation and insomnia. Human plasma half-life is not established.

The oral heavy zone begins at 20 mg, only 5 mg above the top of the strong band (15–20 mg). Light and threshold both start at 3 mg. This is a low-milligram tryptamine, not a 4-HO-MET dose scaled by the similar name.

Quantitatives Wirkungsspektrum (Literaturdaten)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
3 mg
Cognitive & Sensory

A light mood and body shift, increased tactile notice, still mostly functional.

Somatic & Autonomic

Mild nausea or stomach tightness and a small pulse increase.

Light
3–7 mg
Cognitive & Sensory

Warm sociability, erotic tactile enhancement, stimulation, and soft sensory brightening.

Somatic & Autonomic

Nausea, jaw tension, dilated pupils, and a stimulated rather than sedated body.

Common Reference
7–15 mg
Cognitive & Sensory

Clear entactogenic and psychedelic effects, enhanced music and touch, some visuals, and a busy mind.

Somatic & Autonomic

Pronounced nausea early on, vasoconstriction (cold hands), sweating, and a sustained faster heartbeat.

Strong
15–20 mg
Cognitive & Sensory

Intense stimulation, anxiety or elevated dopaminergic tone, tactile overload, and a psychedelic state that is hard to treat as 'just body warmth'.

Somatic & Autonomic

Strong nausea or vomiting, muscle tension, marked vasoconstriction, and restlessness.

Heavy / Toxic Zone
20 mg+
Cognitive & Sensory

Overwhelming confusion, panic, and a loss of the manageable erotic/stimulant character.

Somatic & Autonomic

Severe nausea, headache, significant blood-pressure rise, and seizure risk with tramadol, lithium, or an MAOI.

Wechselwirkungsmatrix — Niemals kombinieren

Lebensgefahr — Niemals kombinieren

MAOIs (moclobemide, phenelzine, tranylcypromine, harmala alkaloids)

Monoamine oxidase inhibition removes the main brake on serotonin while a 5-HT2A agonist is active, producing prolonged, unpredictable intensity, hypertensive reactions, and serotonin toxicity.

Lithium

Lithium combined with serotonergic psychedelics is associated with seizures and poorly responsive medical emergencies even at otherwise ordinary amounts.

Tramadol, DXM, and other seizure-threshold or serotonin-stacking drugs

Additive seizure-threshold lowering and serotonergic load. Tramadol is repeatedly flagged on PsychonautWiki interaction lists for this class.

Hohes Risiko — Vermeiden

Other stimulants and 5-MeO-DMT

Stacks vasoconstriction and confusion. 5-MeO-DMT is a different, much sharper compound and is not a top-up for moxy.

Alcohol

Worsens nausea and judgment across a 5–8 hour course.

Vorsicht / Abschwächung

SSRIs and SNRIs

Often blunt psychedelic intensity while the physical load remains; they are not a reliable 'off switch' and do not make combinations with releasers safe.

Cannabis

Frequently deepens visuals, looping thoughts, and anxiety, including at amounts that felt moderate before cannabis.

Isomeren- & Strukturvergleich

5-MeO-MiPT is orally active and lasts 5–8 hours at 7–15 mg common, with more stimulation and less color than 4-HO-MiPT (common 15–25 mg). It is far less abrupt than vaporized 5-MeO-DMT (common 6–12 mg, 20–40 minutes) but shares the 5-methoxy warning about MAOIs. The N-isopropyl group is the same idea as in 4-HO-MiPT, not a reason to copy that dose.

Stabilität & Lagerung

Form: White, off-white, or tan crystalline powder or clumps as the freebase or a salt. · Salts dissolve in water; the freebase is more soluble in organic solvents and can be vaporized, which PsychonautWiki lists as a separate, not milder, route.

Airtight, cool, and dark. The oral active range begins at 3 mg, so a milligram scale plus a written label is part of storage safety.

Cross-Tolerance & Dependence Profile

Psychedelic tolerance builds quickly, halves in about 3 days, and is near baseline in about 7 days, with cross-tolerance to other 5-HT2A psychedelics. The stimulant edge can encourage repeated exposure; the 20 mg heavy line is close to the strong band, so repeated exposure is how overshoots happen.

Analytische & toxikologische Monographie

5-MeO-MiPT (moxy; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine; CAS 96096-55-8, PubChem CID 2763156) is a 5-methoxy tryptamine supplied as pure powder or crystals (C15H22N2O, 246.35 g/mol). Unlike 5-MeO-DMT it is orally active, via 5-HT1A/5-HT2A agonism with a stimulating, tactile, low-visual profile. PsychonautWiki oral bands are threshold 3 mg, light 3–7 mg, common 7–15 mg, strong 15–20 mg, and heavy from 20 mg. Onset is 20–40 minutes and the total course is 5–8 hours, with nausea and vasoconstriction as ordinary features rather than rare side notes. It is not 4-HO-MiPT and not a milligram-matched stand-in for 5-MeO-DMT. Do not combine with MAOIs, lithium, or tramadol.

Chemische Struktur und Molekülprofil

5-MeO-MiPT (N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine) ist eine Referenzverbindung aus der Stoffklasse Tryptamin-Derivate mit der Summenformel C15H22N2O und einer molaren Masse von 246.35 g/mol. Die Stammverbindung wird unter der CAS-Nummer 96096-55-8 sowie in der NCBI-PubChem-Datenbank unter CID 2763156 geführt (Standard-InChIKey: HEDOODBJFVUQMS-UHFFFAOYSA-N).

Quellen

Referenztoxikologie und Sicherheitsprofil

Laut dokumentierten Referenzdaten (PubChem / PsychonautWiki, CC BY 4.0) gehört 5-MeO-MiPT zur chemischen Klasse Substituted tryptamines. Oxidationsempfindliches Tryptamin-Derivat; Referenzquellen vermerken strikte Kontraindikationen mit MAO-Hemmern (MAOI). Abhängigkeitspotenzial (PsychonautWiki): nicht gewohnheitsbildend. Dokumentierte Kreuztoleranz: psychedelic. Beim Umgang im Labor sind geeignete persönliche Schutzausrüstung und das Sicherheitsdatenblatt (SDB) zu beachten.

Quellen

Analytischer Verwendungszweck und Laborhinweis

Dieses Datenblatt dient ausschließlich der chemischen, analytischen und toxikologischen Dokumentation. Das Material ist nicht für den menschlichen Verzehr bestimmt. Ein Forschungshinweis begründet keinen Rechtsstatus.

Quellen

Dokumentierte Wechselwirkungen und Kontraindikationen

Hohes Risiko / Gefährliche Kombinationen

Unsichere Kombinationen (erhöhtes Risiko)

Ungeklärte Wechselwirkungen (Vorsicht geboten)